Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 1/20 | 0.81 |
| ▸ | XDH | P47989 | 1/20 | 0.81 |
| ▸ | CNR1 | P21554 | 1/20 | 0.74 |
| ▸ | HPGD | P15428 | 8/20 | 0.70 |
| ▸ | IGF1R | P08069 | 2/20 | 0.65 |
| ▸ | GSK3B | P49841 | 1/20 | 0.64 |
| ▸ | MMP13 | P45452 | 1/20 | 0.60 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.60 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | MAOA | P21397 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 1/20 | 0.58 |
| ▸ | PIM1 | P11309 | 1/20 | 0.57 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.57 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14757 | 0.90 | IDH1 (1.00) | IDH1XDHCNR1HPGDGSK3B | |
| SCHEMBL1250306 | 0.89 | HPGD (0.74) | IDH1XDHHPGDMMP13PTPN1 | |
| SCHEMBL1250305 | 0.89 | HPGD (0.74) | IDH1XDHHPGDMMP13PTPN1 | |
| SCHEMBL1248797 | 0.86 | CNR1 (0.81) | CNR1HPGDIGF1RMMP13ADAMTS5 | |
| SCHEMBL1248799 | 0.86 | CNR1 (0.81) | CNR1HPGDIGF1RMMP13ADAMTS5 | |
| SCHEMBL9433307 | 0.86 | CNR1 (0.81) | CNR1HPGDIGF1RMMP13ADAMTS5 | |
| SCHEMBL8159449 | 0.84 | HPGD (0.81) | CNR1HPGDIGF1RMMP13ADAMTS5 | |
| SCHEMBL8159450 | 0.84 | HPGD (0.81) | CNR1HPGDIGF1RMMP13ADAMTS5 | |
| SCHEMBL8877394 | 0.83 | IGF1R (0.64) | IDH1XDHCNR1HPGDIGF1R | |
| SCHEMBL6923859 | 0.81 | CNR1 (0.80) | CNR1HPGDIGF1RMMP13ADAMTS5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9982309-B2 | Method for treating cell proliferation related disorders | AGIOS PHARMACEUTICALS, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-20170044620-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | SERVIER PHARMACEUTICALS LLC | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044620-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | IDH2, IDH1, IDH3B | IDH1 2/4885XDH 1723/4885CNR1 3757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.